Skip to main content Skip to search Skip to main navigation

EMA: New guideline on the quality of water for pharmaceutical use

On 20 July 2020, EMA published the final 10-page Guideline on the quality of water for pharmaceutical use.
The date of entry into force will be 1 February 2021.

On that date the guideline replaces 

  • the Note for guidance on quality of water for pharmaceutical use from 1 May 2002 

  • the CPMP Position Statement on the quality of water used in the production of vaccines for parenteral use from 20 October 2003.

It takes into account the following interim changes to the European Pharmacopoeia: 

  • the revised monograph on Water for Injection (0169), which offers the possibility of using processes other than distillation for WFI (Water for Injection), e. g. reverse osmosis 

  • new monograph on water for the production of extracts (2249) and 

  • the suppression of the monograph for HPW, highly purified water (1927) 

It also reflects the expectations for the minimum acceptable water quality in the manufacture of active ingredients and medicinal products for human and veterinary use. 

The guideline is to be understood as a guideline for the pharmaceutical use of different water qualities in the manufacture of active substances and medicinal products for use in human and veterinary medicine. The document also applies to ATMPs (Advanced Therapy Medicinal Products) and can in general also be applied to investigational medicinal products (IMPs).

Chapter 5 “Quality of Water for Pharmaceutical Use” contains tables with examples for different water qualities such as 

  • Water present as an excipient in the final formulation 

  • Water used during manufacture of active substances and medicinal products excluding water present as an excipient in the final formulation 

  • Water used for cleaning/rinsing of equipment, containers and closures 

Read the new guideline together with the corresponding Q&A paper Questions and answers on production of water for injections by nondistillation methods – reverse osmosis and biofilms and control strategies"This Q&A was published in 2017 after the revision of the WFI monograph. 


Source: 

EMA: Guideline on the quality of water for pharmaceutical use 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

What are the Core Tasks of Human Resource Management?

What are the Core Tasks of Human Resource Management?

Here's the answer:
Read more
European GMP Regulations: Ongoing Changes and What Lies Ahead

European GMP Regulations: Ongoing Changes and What Lies Ahead

At the 2026 ISPE European Annual Conference in Copenhagen, Brendan Cuddy (EMA) provided a concise update on current European GMP regulatory developments and the work of the GMP/GDP Inspectors Working Group (GMDP IWG).
Read more
EMA: Scientific Guideline on Development and Manufacture of Synthetic Peptides

EMA: Scientific Guideline on Development and Manufacture of Synthetic Peptides

The EMA has published the final version of the scientific guideline „Development and manufacture of synthetic peptides“.
Read more
EU: Strengthening Pharmaceutical Supply Chains and Global Health Resilience

EU: Strengthening Pharmaceutical Supply Chains and Global Health Resilience

The European Commission has published a new communication on reinforcing global health resilience, with a strong focus on resilient pharmaceutical supply chains, expanded manufacturing capacity, and security of supply for critical health products.
Read more
Annex 22: EMA Workshop on AI in GMP

Annex 22: EMA Workshop on AI in GMP

The European Medicines Agency (EMA) will hold a two-day multistakeholder workshop on 30 June and 1 July 2026 to gather expert input for the development of Annex 22 of the EU GMP Guide on the use of artificial intelligence (AI) in medicines manufacturing.
Read more
EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

Commission Implementing Regulation (EU) 2026/977 of 4 May 2026 further specifies requirements for notified bodies under the MDR and IVDR frameworks and aims to promote a more harmonised implementation across the European Union.
Read more
Previous
Next